• 1
    Lee J, Pena MM, Nose Y, Thiele DJ. Biochemical characterization of the human copper transporter Ctr1. J Biol Chem 2001; 277: 43807.
  • 2
    Klomp AE, Tops BB, Van Denberg IE, Berger R, Klomp LW. Biochemical characterization and subcellular localization of human copper transporter 1 (hCTR1). Biochem J 2002; 364: 497505.
  • 3
    Palmiter RD. The elusive function of metallothioneins. Proc Natl Acad Sci USA 1998; 95: 842830.
  • 4
    Kelley EJ, Palmiter RJ. A murine model of Menkes disease reveals a physiological function of metallothionein. Nat Genet 1996; 13: 21922.
  • 5
    Rae T, Schmidt P, Pufahl R, Culotta VC, O'Halloran TV. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999; 284: 8058.
  • 6
    Huffman DL, O'Halloran TV. Function, structure, and mechanism of intracellular copper trafficking proteins. Annu Rev Biochem 2002; 70: 677701.
  • 7
    Hamza I, Schaefer M, Klomp LW, Gitlin JD. Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. Proc Natl Acad Sci USA 1999; 96: 13 363–8.
  • 8
    Larin D, Mekios C, Das K, Ross B, Yang AS, Gilliam TC. Characterization of the interaction between the Wilson and Menkes disease proteins and the cytoplasmic copper chaperone, HAH1p. J Biol Chem 1999; 274: 28 497–504.
  • 9
    Wernimont AK, Huffman DL, Lamb AL , O'Halloran TV, Rosenzweig AC. Structural basis for copper transfer by the metallochaperone for Menkes/Wilson disease proteins. Nat Struct Biol 2000; 7: 76671.
  • 10
    Walker JM, Tsivkovskii R, Lutsenko S. Metallochaperone Atox1 transfers copper to the NH2-terminal domain of the Wilson's disease protein and regulates its catalytic activity. J Biol Chem 2002; 277: 27 953–9.
  • 11
    Lutsenko S, Petris MJ. Function and regulation of the mammalian copper-transporting ATPases: insights from biochemical and cell biological approaches. J Membr Biol 2003; 191: 112.
  • 12
    Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995; 9: 2107.
  • 13
    Maier-Dobersberger T, Ferenci P, Polli C, et al. Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med 1997; 127: 216.
  • 14
    Caca K, Ferenci P, Kuhn HJ, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype–genotype analysis. J Hepatol 2001; 35: 57581.
  • 15
    Firneisz G, Lakatos PL, Szalay F, Polli C, Glant TT, Ferenci P. Common mutations of ATP7B in Wilson disease patients from Hungary. Am J Med Genet 2002; 108: 238.
  • 16
    Schaefer M, Hopkins R, Failla M, Gitlin JD. Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver. Am J Physiol 1999; 276: G63946.
  • 17
    Tao YT, Gitlin JD. Hepatic copper metabolism: insights from genetic disease. Hepatology 2003; 37: 12417.
  • 18
    McCullough AJ, Fleming CR, Thistle JL, et al. Diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology 1983; 84: 1617.
  • 19
    Berman DH, Leventhal RI, Gavaler JS, Cadoff EM, Van Thiel DH. Clinical differentiation of fulminant wilsonian hepatitis from other causes of hepatic failure. Gastroenterology 1991; 100: 112934.
  • 20
    Scott J, Gollan JL, Samourian S, Sherlock S. Wilson's disease, presenting as chronic active hepatitis. Gastroenterology 1978; 74: 64551.
  • 21
    Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease. A prospective study in 45 cases. J Neurol 1991; 238: 2817.
  • 22
    Scheinberg IH, Sternlieb I. Wilson's Disease. Vol. 23. Major Problems in Internal Medicine. Philadelphia: Saunders, 1984.
  • 23
    Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson disease. Lancet 2004 (in press).
  • 24
    Sternlieb I. Perspectives on Wilson's disease. Hepatology 1990; 12: 12349.
  • 25
    Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser–Fleischer rings. Neurology 1996; 46: 10403.
  • 26
    Van Wassenaer-van Hall HN, Van Den Heuvel AG, Algra A, Hoogenraad TU, Mali WP. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996; 198: 5316.
  • 27
    Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113: 2128.
  • 28
    Cauza E, Maier-Dobersberger Th, Ferenci P. Plasma ceruloplasmin as screening test for Wilson's disease. J Hepatol 1997; 27: 35862.
  • 29
    Da Costa CM, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 1992; 15: 60915.
  • 30
    Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Final report of the Proceedings of the Working Party at the 8th International Meeting on Wilson Disease and Menkes Disease, Leipzig/Germany, 2001. Liver Int 2003; 23: 13942.
  • 31
    Ludwig J, Moyer TP, Rakela J. The liver biopsy diagnosis of Wilson's disease. Am J Clin Pathol 1994; 102: 4436.
  • 32
    Ferenci P. Genotype–phenotype correlations in Wilson disease. J Hepatol 2002; 36(Suppl. 1): 158.
  • 33
    Yurdaydin C, Demir K, Bozkaya H, et al. Mutation analysis in Turkish patients with Wilson disease. Hepatology 2003 (in press).
  • 34
    Loudianos G, Dessi V, Lovicu M, et al. Molecular characterization of Wilson disease in the Sardinian population — evidence of a founder effect. Hum Mutat 1999; 14: 294303.
  • 35
    Kim EK, Yoo OJ, Song KY, et al. Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease. Hum Mutat 1998; 11: 2758.
  • 36
    Nanji MS, Nguyen VT, Kawasoe JH, et al. Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 1997; 60: 14236.
  • 37
    Maier-Dobersberger Th, Rack S, Granditsch G, et al. Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis. Gastroenterology 1995; 109: 20158.
  • 38
    Cox DW. Molecular advances in Wilson disease. Prog Liver Dis 1996; 14: 24664.
  • 39
    Roberts EA, Schilsky ML. AASLD practice guidelines. A practice guideline on Wilson disease. Hepatology 2003; 37: 147592.
  • 40
    Walshe JM, Yealland M. Chelation treatment of neurological Wilson's disease. Q J Med 1993; 86: 197204.
  • 41
    Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 1987; 317: 20913.
  • 42
    Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996; 53: 101725.
  • 43
    Condomina J, Zornoza-Sabina T, Granero L, Polache A. Kinetics of zinc transport in vitro in rat small intestine and colon: interaction with copper. Eur J Pharm Sci 2002; 16: 28995.
  • 44
    Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. Treatment of Wilson's disease with zinc. X. Intestinal metallothionein induction. J Lab Clin Med 1992; 120: 3806.
  • 45
    Lee DY, Brewer GJ, Wang Y. Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 1989; 114: 63945.
  • 46
    Ferenci P. Zinc treatment of Wilson's disease. In: Kruse-JarresJD, SchölmerichJ, eds. Zinc and Diseases of the Digestive Tract. Lancaster: Kluwer Academic Publishers, 1997: 11724.
  • 47
    Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. The treatment of Wilson's disease with zinc. J Lab Clin Med 1999; 134: 3224.
  • 48
    Brewer GJ, Yuzbasiyan Gurkan V, Lee DY, Appelman H. Treatment of Wilson's disease with zinc. VI. Initial treatment studies. J Lab Clin Med 1989; 114: 6338.
  • 49
    Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with d-penicillamine and zinc sulphate. J Neurol 1996; 243: 26973.
  • 50
    Sokol RJ, Twedt D, McKim JM Jr, et al. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology 1994; 107: 178898.
  • 51
    Grimm G, Madl Ch, Katzenschlager R, Oder W, Ferenci P, Gangl A. Detailed evaluation of brain dysfunction in patients with Wilson's disease. EEG Clin Neurophysiol 1992; 82: 11924.
  • 52
    Grimm G, Oder W, Prayer L, Ferenci P, Madl Ch. Prospective follow-up study in Wilson's disease. Lancet 1990; 336: 9634.
  • 53
    Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 1994; 19: 5837.
  • 54
    Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson's disease. J Hepatol 1995; 23: 37381.
  • 55
    Eghtesad B, Nezakatgoo N, Geraci LC, et al. Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg 1999; 5: 46774.
  • 56
    Guarino M, Stracciari A, D'Alessandro R, Pazzaglia P. No neurological improvement after liver transplantation for Wilson's disease. Acta Neurol Scand 1995; 92: 4058.
  • 57
    Bax RT, Hassler A, Luck W, et al. Cerebral manifestation of Wilson's disease successfully treated with liver transplantation. Neurology 1998; 51: 8635.